Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The event offers live dial-in, instant telephone access, and a webcast via investor relations. A replay will be available on Corvus' website for 90 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
CRVS gained 1.77% while several biotech peers were also positive (e.g., PRTA +5.34%, ALMS +1.62%), but no names appeared on the momentum scanner, suggesting a stock-specific move rather than a sector-wide rotation.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 04 | Q3 2025 results | Positive | -1.4% | Q3 2025 financials and clinical milestones, with runway into Q4 2026. |
| Oct 28 | Q3 call scheduled | Neutral | +1.2% | Announcement of Nov 4, 2025 business update and Q3 2025 results call. |
| Aug 07 | Q2 2025 results | Positive | +4.4% | Q2 2025 results with positive soquelitinib data and stronger cash balance. |
| Jul 31 | Q2 call scheduled | Neutral | -1.7% | Scheduling of Aug 7, 2025 business update and Q2 2025 results call. |
| May 08 | Q1 2025 results | Positive | +32.2% | Q1 2025 results with favorable Phase 1 data and strengthened cash position. |
Earnings updates and results have generally coincided with modestly positive or strong upside moves, with only one recent earnings report showing a small negative reaction.
Over the past year, Corvus has repeatedly paired business updates with quarterly financial results, highlighting progress for soquelitinib and a T‑cell lymphoma Phase 3 program. Prior earnings releases on May 8, 2025, Aug 7, 2025 and Nov 4, 2025 emphasized strengthening cash positions, extended runway into Q4 2026, and increasing R&D spend. Scheduling calls ahead of results, as on Jul 31 and Oct 28, 2025, has been a recurring pattern, and the current announcement follows that same cadence.
Historical Comparison
In the past year, CRVS issued 5 earnings-related updates, with an average move of 6.93%. Today’s scheduling release fits the established pattern of pre-call announcements tied to business updates.
Earnings updates have traced soquelitinib’s clinical progress from early Phase 1 data toward larger trials, while cash balances and warrant exercises extended runway into Q4 2026, framing today’s Q4/FY 2025 call as the next checkpoint.
Market Pulse Summary
This announcement sets the timeline for Corvus’ Q4 and full-year 2025 business update on March 12, 2026, continuing its practice of pairing financials with clinical progress commentary. Prior results highlighted growing R&D investment, positive soquelitinib data and cash balances supporting operations into Q4 2026. Investors may focus on how recent large offerings, updated runway expectations and any new trial milestones shape the company’s funding profile and development trajectory during the upcoming call.
AI-generated analysis. Not financial advice.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals:
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com and LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus Pharmaceuticals (CRVS) report its Q4 2025 financial results?
How can investors access the Corvus (CRVS) March 12, 2026 conference call and webcast?
Will Corvus (CRVS) provide a replay of the March 12, 2026 webcast and for how long?
What topics will Corvus (CRVS) cover during the March 12, 2026 business update?
Is there an instant telephone access option for the Corvus (CRVS) March 12, 2026 event?
